Nucleic acids are a promising type of therapeutic for the treatment of a wide range of
conditions, including cancer, but they also pose many delivery challenges. For efficient and …

Introduction Convection-enhanced delivery (CED) is a method of targeted, local drug
delivery to the central nervous system (CNS) that bypasses the blood-brain barrier (BBB) …

Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor
prognosis. Attempts to develop targeted therapies have been hindered because the blood …

Adenoviruses have been characterized extensively since their initial description in the early
1950s (Hillemann & Werner, 1954; Rowe et al., 1953) and there is now a panoply of …

Gene therapy for neurological disorders has attracted significant interest as a way to reverse
or stop various disease pathologies. Typical gene therapies involving the central and …

Alternatives to efficient viral vectors in gene therapy are desired because of their poor safety
profiles. Chitosan is a promising non-viral nucleotide delivery vector because of its …

While initial approaches to adoptive T cell therapy relied on the identification and expansion
of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy …

ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT
CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015 …

Background Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that
carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune …

Although rodent glioblastoma (GBM) models have been used for over 30 years, the extent to
which they recapitulate the characteristics encountered in human GBMs remains …